| Similar Articles |
|---|
 |
The Motley Fool
September 26, 2006
Brian Lawler |
CVT's Looming Date With Destiny A pivotal trial for its lead drug, Ranexa, is nearing completion. Investors, take note.   |
The Motley Fool
March 7, 2007
Brian Lawler |
A CV Therapeutics Buying Opportunity? Shares of CV Therapeutics tank after reporting mixed results from a pivotal clinical trial for its lead drug. |
The Motley Fool
July 10, 2006
Brian Lawler |
CV Therapeutics Gets Greenlighted A final trial could secure full FDA approval for angina drug Ranexa. Investors, take note. |
The Motley Fool
November 7, 2007
Brian Lawler |
Turnaround Time for CVT CV Therapeutics announces in its third-quarter financial results that it plans to have a better 2008; its angina drug shows promise for treating diabetics. Investors, take note. |
The Motley Fool
February 13, 2007
Brian Lawler |
CVT, We Wait for Thee CV Therapeutics' angina treatment could be set for a big boost. But what investors are getting with CVT today is a specialty pharma that is rapidly burning the cash on its balance sheet. |
The Motley Fool
September 17, 2008
Brian Lawler |
CV Therapeutics Expands Ranexa's Reach CVT announces that it has finally found a European marketing partner for its angina treatment Ranexa. |
The Motley Fool
August 1, 2007
Brian Lawler |
CV Therapeutics' Turnaround Quarter Putting a close to a turnaround second quarter, CV Therapeutics announced its financial results recently. It looks like shareholders are in for some good times. |
The Motley Fool
April 28, 2008
Brian Lawler |
CV Therapeutics Feels the Love CV Therapeutics announces its second regulatory thumbs-up this month, after its lead drug Ranexa was essentially approved in the European Union. |
The Motley Fool
August 1, 2008
Brian Lawler |
Holy Moley, CV Therapeutics! With big successes on the regulatory and financial fronts, CV Therapeutics has had a quarter where everything went right. |
The Motley Fool
April 4, 2005
Karl Thiel |
CV Therapeutics' Great Resume With biotechs in the doldrums, this investor goes hunting. |
The Motley Fool
January 3, 2011
Brian Orelli |
Clinical Trial Results Fail to Inspire Inspire Pharma gets cut in half after a cystic fibrosis trial failure. |
The Motley Fool
April 17, 2008
Brian Lawler |
CVT's Copacetic Cash Management Drugmaker CV Therapeutics signs away a little portion of its royalty stream from a recently approved drug, in order to get a lot back. |
The Motley Fool
May 31, 2011
Brian Orelli |
5 Biotechs With Upcoming Clinical Trial Results Investors willing to stay in these stocks a little while could see substantial gains well ahead of FDA approvals. |
The Motley Fool
March 29, 2010
Brian Orelli |
Look for Companies That Strike First Head-to-head trials, whether they're run by companies or by third parties, can be scary. But the way to make big money is by selling drugs that offer superior benefits, so investors should welcome the onslaught of upcoming comparative trial data. |
The Motley Fool
April 3, 2009
Brian Orelli |
Gilead: Helping Investors Cope With the Market Diversifying seems to be paying off for the drugmaker. |
BusinessWeek
February 2, 2004
Gene G. Marcial |
CV Investors: Take Heart Lately, CV Therapeutics is bouncing around on rumors of what the Food & Drug Administration might do about Ranexa, CV's angina treatment. One New York fund manager, who asked not to be identified, is buying shares because he expects a takeover bid. |
The Motley Fool
April 14, 2008
Brian Lawler |
A Little Delay Goes Away for CVT CV Therapeutics can move ahead, now that it has won marketing approval for its cardiac stress agent regadenoson. |
The Motley Fool
January 28, 2009
Brian Orelli |
M&A Off the Beaten Path CV Theraputics gets courted. |
The Motley Fool
December 9, 2008
Brian Orelli |
The FDA Can't See the Forest or the Trees Forest Laboratories and Cypress Bioscience are still waiting for FDA approval, but now they've got more data to prove their point. |
